Introduction:

Mastocytosis is characterized by the accumulation of mast cells in various organs, especially in the skin, with alteration of the immune response. In Las Tunas province, it represents 5.17% of genodermatoses. COVID-19, caused by the SARS-CoV-2 virus, shows high lethality in the world and also affects the pediatric population. Cases that evolve into the complicated form of the disease are those with associated comorbidities and immune system disorders.

Objective:

To compile information on the main risks for children diagnosed with mastocytosis and COVID-19 infection.

Methods:

The literature available in Scopus, SciELO, PubMed Central, MedlinePlus, Clinicalkey, LILACS, Orphanet, OMIM, WHO, PAHO, and MINSAP was reviewed. The descriptors used were: medical genetics, genetic dermatological diseases, mastocytosis, human coronavirus, SARS-CoV-2, COVID-19. During the review process, 5 books and 21 articles published in the last 5 years were consulted.

Analysis and synthesis of information:

Based on the etiopathogenesis and clinical manifestations of mastocytosis and COVID-19, the main risks for the child diagnosed with mastocytosis are shown, such as urticarial manifestations, anaphylaxis and mast cell activation syndrome that can lead the child to develop severe COVID-19. Elements to take into account to treat these patients are included.

Conclusions:

In infants diagnosed with mastocytosis there are risks of developing complications due to COVID-19 infection, and recognizing them, allows improving their care.

        · resumen en Español     · texto en Español     · Español ( pdf )